Despite End-Market Concerns, Genomic Tools Vendors Keep up R&D Pace | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Despite an uncertain economy and softness in key end markets, genomic tools and molecular diagnostics firms continued to invest in new technologies as R&D spending through the first half of 2011 rose 13 percent year over year among the firms tracked in the GenomeWeb Daily News Index.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.